

RESEARCH ARTICLE

# Interplay of strain and race/ethnicity in the innate immune response to *M. tuberculosis*

P. Nahid<sup>1\*</sup>, L. G. Jarlsberg<sup>1</sup>, M. Kato-Maeda<sup>1</sup>, M. R. Segal<sup>2</sup>, D. H. Osmond<sup>2</sup>, S. Gagneux<sup>3</sup>, K. Dobos<sup>4</sup>, M. Gold<sup>5</sup>, P. C. Hopewell<sup>1</sup>, D. M. Lewinsohn<sup>6,7\*</sup>

**1** Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, United States of America, **2** Department of Epidemiology & Biostatistics, University of California, San Francisco, United States of America, **3** Swiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, University of Basel, Basel, Switzerland, **4** Colorado State University, Department of Microbiology, Immunology & Pathology, Fort Collins, CO, United States of America, **5** Department of Research, Veterans Affairs Portland Health Care Center, Portland, Oregon, United States of America, **6** Department of Pulmonary and Critical Care Medicine, Oregon Health and Sciences University, Portland, Oregon, **7** Department of Research, Veterans Affairs Portland Health Care Center, Portland, Oregon, United States of America

\* [pnahid@ucsf.edu](mailto:pnahid@ucsf.edu) (PN); [lewinsod@ohsu.edu](mailto:lewinsod@ohsu.edu) (DML)



**OPEN ACCESS**

**Citation:** Nahid P, Jarlsberg LG, Kato-Maeda M, Segal MR, Osmond DH, Gagneux S, et al. (2018) Interplay of strain and race/ethnicity in the innate immune response to *M. tuberculosis*. PLoS ONE 13(5): e0195392. <https://doi.org/10.1371/journal.pone.0195392>

**Editor:** Olivier Neyrolles, Institut de Pharmacologie et de Biologie Structurale, FRANCE

**Received:** October 25, 2017

**Accepted:** March 21, 2018

**Published:** May 22, 2018

**Copyright:** ©2018 Nahid et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported in part by NIH grants: NHLBI K23HL092629 (PN) and The National Center for Research Resources grant number KL2RR024130 (PN). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official view of NCRH or NIH.

## Abstract

### Background

The roles of host and pathogen factors in determining innate immune responses to *M. tuberculosis* are not fully understood. In this study, we examined host macrophage immune responses of 3 race/ethnic groups to 3 genetically and geographically diverse *M. tuberculosis* lineages.

### Methods

Monocyte-derived macrophages from healthy Filipinos, Chinese and non-Hispanic White study participants (approximately 45 individuals/group) were challenged with *M. tuberculosis* whole cell lysates of clinical strains Beijing HN878 (lineage 2), Manila T31 (lineage 1), CDC1551 (lineage 4), the reference strain H37Rv (lineage 4), as well as with Toll-like receptor 2 agonist lipoteichoic acid (TLR2/LTA) and TLR4 agonist lipopolysaccharide (TLR4/LPS). Following overnight incubation, multiplex assays for nine cytokines: IL-1 $\beta$ , IL-2, IL-6, IL-8, IL-10, IL-12p70, IFN $\gamma$ , TNF $\alpha$ , and GM-CSF, were batch applied to supernatants.

### Results

Filipino macrophages produced less IL-1, IL-6, and more IL-8, compared to macrophages from Chinese and Whites. Race/ethnicity had only subtle effects or no impact on the levels of IL-10, IL-12p70, TNF $\alpha$  and GM-CSF. In response to the Toll-like receptor 2 agonist lipoteichoic acid (TLR2/LTA), Filipino macrophages again had lower IL-1 and IL-6 responses and a higher IL-8 response, compared to Chinese and Whites. The TLR2/LTA-stimulated Filipino macrophages also produced lower amounts of IL-10, TNF $\alpha$  and GM-CSF. Race/ethnicity had no impact on IL-12p70 levels released in response to TLR2/LTA. The responses to TLR4 agonist lipopolysaccharide (TLR4/LPS) were similar to the TLR2/LTA responses,

**Competing interests:** The authors have declared that no competing interests exist.

for IL-1, IL-6, IL-8, and IL-10. However, TLR4/LPS triggered the release of less IL-12p70 from Filipino macrophages, and less TNF $\alpha$  from White macrophages.

## Conclusions

Both host race/ethnicity and pathogen strain influence the innate immune response. Such variation may have implications for the development of new tools across TB therapeutics, immunodiagnostics and vaccines.

## Introduction

Genotyping of *Mycobacterium tuberculosis* (*M. tuberculosis*) has shown that lineages of the organism have predilections for certain geographic distributions and dominate certain geographic areas [1–4]. Members of the East Asian lineage (that includes the Beijing family) are predominant in East Asia, members of the Indo-Oceanic lineage are predominant in the Philippines and around the rim of the Indian Ocean [5], and members of the *M. africanum* West Africa I and II are largely restricted to West Africa [1, 6]. This global distribution of strains may not be random or based solely upon variabilities in virulence, but may be partly determined by the genetics, epigenetics and other factors of the host and the microbe, both of which are under natural selection forces.

Successful containment of infection with *M. tuberculosis* is dependent on innate immune responses, as these responses play a central role in the acquisition of the adaptive T cell response, in granuloma formation, and ultimately in the containment of intracellular growth of *M. tuberculosis* [7]. The cells responsible for the containment of intracellular infection, dendritic cells and alveolar macrophages, are also the preferred intracellular host of *M. tuberculosis*. Central to the function of these cells is responsiveness to bacterially derived patterns, that are recognized by Toll-like receptors (TLR). There is evidence that TLRs play an important role in the host immune response to *M. tuberculosis* [7]. Alveolar macrophages are the first responders to inhalation of tubercle bacilli and represent an important component of the innate response to *M. tuberculosis* infection. Exposure of macrophages to *M. tuberculosis* results in the secretion of cytokines, including TNF $\alpha$ , GM-CSF, IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, IL-8, IL-10, and IL-12p70, that play key roles in granuloma formation [8–10]. Two members of the mammalian TLR family, TLR2 and possibly TLR4, have been found to recognize mycobacterial products and to mediate macrophage activation and the ensuing production of particular cytokines [7, 11]. The discovery of TLR polymorphisms that are associated with race/ethnicity and response to particular pathogens, raises the distinct possibility that there are ethnicity-specific differences in TLR2 and/or TLR4, resulting in differential innate responses to *M. tuberculosis* strains [12–16]. Such immunologic differences in innate response are of interest given the molecular epidemiologic studies demonstrating differences in the transmissibility and virulence of *M. tuberculosis* based on strain [17] [18–20]. Differential activation through TLRs could have a significant impact on the host response to infection with *M. tuberculosis*, and ultimately to disease progression.

Our study explores the interaction of host and pathogen factors on the innate immune response. Based on the molecular epidemiology of TB in San Francisco, which includes a sizable population of Asian patients [17, 21], we selected 3 race/ethnic groups, Filipinos, Chinese, and non-Hispanic Whites for inclusion in our study. From these healthy donors, macrophages were isolated and treated with lysates from 4 *M. tuberculosis* strains, comprising 3

predominant lineages identified in San Francisco (East Asian [Beijing HN878], Indo-Oceanic [Manila T31] and EuroAmerican [CDC1551]), and one laboratory reference strain (H37Rv), or with agonists of TLR2 (lipoteichoic acid LTA) or TLR4 (lipopolysaccharide LPS). A total of 9 cytokines were measured. This study adds to the growing body of evidence that differential innate immune responses contribute to ethnicity-associated differences in TB susceptibility.

## Methods

### Ethics statement

The “Innate Immunity to TB” (IITB) study protocol was reviewed and approved by the committee on human research at the University of California, San Francisco (CHR# H45279-29459). Written informed consent was obtained from all study participants.

### Study design and participants

Healthy volunteers, aged 18 to 55, self-identifying as Chinese, Filipino, or non-Hispanic White were invited to participate in the study. Recruitment was through bulletin board postings at the Schools of Dentistry, Medicine, Nursing, Pharmacy, Physical Therapy of the University of California, San Francisco, and at the undergraduate and graduate schools of San Francisco State University. Between 2009 and 2011, all consenting volunteers meeting inclusion and having no exclusion criteria were consecutively enrolled into IITB. Recruitment continued until 50 participants per race/ethnic group were enrolled. All volunteers completed a standardized questionnaire reviewing demographics, health history as well as information on potential risk factors for TB. All volunteers reported the race/ethnicity of their biological parents and grandparents, and only those identifying both generations as Chinese, Filipino or non-Hispanic White were eligible for participation in the study. Those reporting a history of active TB, evidence of prior TB on chest radiograph, vaccination with *Mycobacterium bovis* bacillus Calmette-Guérin (BCG) vaccine in the past 15 years, co-morbid conditions including diabetes, renal disease, cancer, hepatitis, HIV/AIDS, or other moderate or high risk characteristics associated with TB, such as homelessness or history of incarceration, significant alcohol use (greater than 2 drinks per day), tuberculin skin testing within past 6 months, or treatment with any immunomodulating agents such as corticosteroids, were not eligible to participate. All participants had IFN- $\gamma$  release assay testing, specifically QuantiFERON-Gold® (QFT), for latent TB infection at the time of study enrollment.

### Mycobacterial strains, TLR agonists

Whole cell lysates of Beijing HN878, Manila T31, CDC1551, and H37Rv, were obtained from gamma-irradiated cells as described previously [22]. The total protein content from each whole cell lysate batch was quantified by bicinchoninic acid assay (ThermoFisher Scientific, Waltham, MA), and samples were portioned into individual 10 mg vials and stored at -80°C until use. Certificates of Analysis and Product Information Sheets for whole cell lysates are available through the National Institute of Allergy and Infectious Diseases funded BEI Resources (<http://www.beiresources.org/>; catalog numbers: NR-14820, NR-14821, NR-14824, NR-36496).

### Isolation, culture and ex vivo stimulation of Monocyte Derived Macrophages (MDMs)

For each study participant, phlebotomy was performed to fill four BD Vacutainer® CPT™ Cell Preparation Tube with Sodium Citrate (Becton, Dickinson and Company, Franklin Lakes, NJ),

No. 362761). Whole blood was processed according to manufacturer guidance for the separation of mononuclear cells. Monocytes were prepared from freshly drawn blood samples through negative selection using the Miltenyi Biotec Monocyte Isolation Kit II, which provides an indirect magnetic labeling approach for the isolation of untouched monocytes from human peripheral blood mononuclear cells (PBMCs). Monocytes were counted and resuspended at  $5 \times 10^5$ /ml in 10% vol/vol human serum (HuS), and then plated at 500,000/well in ultralow adherence plates, without stimulation, and incubated at 37°C with CO<sub>2</sub> for 72 hours to obtain enrichment of monocyte-derived macrophages (MDMs) through adherence. Upon harvesting of MDMs, viability was assessed by absence of uptake of trypan blue, and purity (ranging 96–98% MDMs) was determined by fluorescence cell sorter (FACS). We further assessed viability on the basis of HLA-DR and CD11c, and T cell contamination on the basis of CD3. MDMs from each study participant, were incubated at  $1 \times 10^5$  for 18 hours with 10 ug / ml whole cell lysate of *M. tuberculosis* strains, and to agonists of TLR2 (10 ug / ml Lipoteichoic acid (LTA) from *S. aureus*, Sigma, L 2515) and TLR4 (50 ng/ml lipopolysaccharide (LPS) from *E. coli* Sigma, L-2880); and culture medium (negative control). Following overnight incubation, supernatants were collected and frozen at -80°C and batch tested using MSD Human ProInflammatory 9-Plex Tissue Culture Kit K15007B-1 (measuring GM-CSF, IFN- $\gamma$ , IL-1 $\beta$ , IL-10, IL-12p70, IL-2, IL-6, IL-8, TNF- $\alpha$ ) run on a Meso Scale Diagnostics MESO QuickPlex SQ 120 instrument.

## Statistics and analysis

Categorical demographic factors were analyzed using chi squared tests; age was compared by race using the Student's t-test. Geometric mean cytokine responses were compared in response to 6 stimulants (4 *M. tuberculosis* strains: H37Rv “reference strain,” CDC1551 “EuroAmerican,” HN878 “East Asian,” and T31 “Indo-Oceanic;” and 2 stimulants on TLR pathways: LTA and LPS) and by race (White, Chinese, and Filipino). For analyses where stimulant was held constant and responses were compared by race, linear regression was used, adjusting for independent factors age and gender. For analyses where race was held constant and participant responses to each stimulant were compared, a general estimating equation (GEE) was added to the linear regression to adjust for responses clustered by participant, in addition to adjusting for age and gender [23]. Multivariable linear regression models were used to assess interplay between race and strain as predictors of cytokine response. P values were adjusted for multiple testing error using the false discovery rate (FDR) method, and significance was defined at the  $p < 0.20$  level [24].

Cytokines were measured in picograms (pg), logged to approximate a normal distribution for analysis, and presented as geometric means with 95% confidence intervals. The upper limit of detection (ULOD) was 10,000 pg for all cytokines; values above the ULOD were set to 10,000 pg. The lower limits of detection (LLOD) were unique for each cytokine; values below the LLOD were left unchanged. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

## Results

### Study population

The study population included 137 healthy donors with mean age 30±8 (range 19–55) years of age. Most were female (n = 99, 72%), and 39% were foreign-born (n = 54). A positive QFT test was uncommon (8%) and more likely to occur among the foreign-born (RR 15.4, 95%CI 2–116). Self-identified race was divided approximately evenly: non-Hispanic White (n = 46),

**Table 1. Demographic characteristics of the study population.**

	White	Chinese	Filipino	White vs. Chinese	<i>p</i> value White vs. Filipino	Chinese vs. Filipino
<b>n (%)</b>	46 (34)	47 (34)	44 (32)			
<b>Mean age±SD (Range)</b>	28.3±6.8 (22–53)	28.7±8.3 (19–55)	32.9±7.1 (22–49)	0.815	0.002	0.005
<b>Female, n (%)</b>	30 (65)	34 (73)	35 (80)	0.459	0.132	0.423
<b>Foreign birth, n (%)</b>	5 (11)	22 (47)	27 (61)	<0.001	<0.001	0.165
<b>QFT positive, n (%)</b>	1 (2)	4 (9)	6 (14)	0.201	0.071	0.436

<https://doi.org/10.1371/journal.pone.0195392.t001>

Chinese (n = 47), or Filipino (n = 44). Filipinos were on average older, and Whites were less likely to be foreign-born (Table 1).

### Cytokine levels

We prepared monocyte-derived macrophages (MDMs) from healthy study participants (n = 137), and incubated the cells with *M. tuberculosis* lysates. The concentration of cytokines released in response to the bacterial lysates were measured using 2 different platforms (Luminex Assay and Meso Scale Discovery immunoassay (MSD); Meso Scale Discovery, Gaithersburg, Maryland) according to manufacturer instructions. Since the cytokine levels and trends were identical for these 2 platforms, we describe our data generated with the MSD kit. We measured a total of 9 cytokines: IL-1β, IL-2, IL-6, IL-8, IL-10, IL-12p70, IFNγ, TNFα, and GM-CSF. As the study was designed to assess macrophage stimulation, the T cell cytokines IFN-γ and IL-2 were included as controls. IFNγ and IL-2, at the lower limit of detection was noted, possibly due T cell contamination.


### Cytokine response to *M. tuberculosis* strain by race/ethnicity

We observed similar patterns across all 4 *M. tuberculosis* strains for IL-1b, IL-6 and IL-8 (Fig 1 and S1 Table). Filipino MDMs produced less IL-1 and IL-6, but more IL-8, compared to MDMs from Whites and Chinese. We observed subtle differences across *M. tuberculosis* strains for TNFα, and GM-CSF. For TNFα, Filipino and White MDMs released less compared to Chinese MDMs, in response to CDC1551. Filipino MDMs released less of this cytokine than Chinese cells, in response to H37Rv, and Filipino MDMs released less TNFα than both Chinese and White MDMs in response to T31. There was no difference by race/ethnicity in the amounts of TNFα released in response to HN878. Only strain T31 triggered the release of different GM-CSF amounts across race/ethnic groups: Filipino MDMs released less of this cytokine, compared to Chinese MDMs (Fig 1 and S1 Table). There were no race/ethnic differences in IL-10 and IL-12p70 responses to any of the *M. tuberculosis* strains (S1 Table).

### Cytokine response to TLR agonists by race/ethnicity

MDMs were incubated for 18 hours with the TLR2 agonist LTA or the TLR4 agonist LPS, and cytokine responses were measured.

In response to TLR2/LTA, Filipino MDMs released lower amounts of IL-1, IL-6, IL-10, TNFα and GM-CSF, but higher amounts of IL-8, compared to Whites and Chinese (Fig 2 and S2 Table). There were no differences by race/ethnicity in the IL-12p70 response to TLR2/LTA (S2 Table).



**Fig 1. Cytokine response of macrophages to *M. tuberculosis* strains by race/ethnicity.** Cytokines released by macrophages derived from healthy individuals of three ethnicities in response to *M. tuberculosis* lysates from four strains. Comparisons are adjusted for age and gender. Brackets indicate FDR-adjusted  $p < 0.20$ .

<https://doi.org/10.1371/journal.pone.0195392.g001>

In response to TLR4/LPS, Filipino MDMs released lower amounts of IL-1, IL-6, IL-10, IL-12p70 but higher amounts of IL-8, compared to Whites and Chinese, while White MDMs released lower amounts of TNF $\alpha$ , compared to Chinese (Fig 2 and S2 Table). There were no differences across race/ethnicity groups in the GM-CSF responses to TLR4/LPS (S2 Table).

### Cytokine response by *M. tuberculosis* strain

We explored the impact of *M. tuberculosis* strain on cytokine responses within each race/ethnicity (S1 Fig and S3 Table). Strain CDC1551 elicited lower levels of IL-1, IL-6, IL-10, TNF $\alpha$  and GM-CSF, and higher levels of IL-8, compared to all other strains, regardless of race/ethnicity. Strain T31 triggered the release of more IL-12p70 compared to the other strains, regardless of race/ethnicity. These data indicate that the clinical *M. tuberculosis* strains CDC1551 and T31 may have different immunogenic profiles, compared to *M. tuberculosis* strains H37Rv and HN878, recognizing that cellular lysates are a crude proxy of infection.


### Cytokine response by both race/ethnicity and strain

Using a multivariable linear regression model predicting response of macrophages to *M. tuberculosis* lysates and race/ethnicity, adjusted for age and gender, Filipino ethnicity was an independent predictor of lower IL-1 and IL-6 response, and of higher IL-8 response compared to Whites (Table 2). CDC1551 strain was an independent predictor of lower IL-1, IL-6, IL-10, TNF $\alpha$ , and GM-CSF response, and of higher IL-8 response compared to the reference strain H37RV. In addition, T31 (Manila strain) was an independent predictor of lower IL-8 activity, and higher activity in IL-1, IL-6, IL-10, IL-12p70, TNF $\alpha$ , and GM-CSF compared to H37RV. HN878 strain was independently predictive of lower IL-8, TNF $\alpha$ , and GM-CSF response compared to H37RV. When multiple testing correction is applied no significant interactions emerged.

### Discussion

In this study of the response of macrophages derived from healthy individuals of 3 race/ethnic groups to *M. tuberculosis* lysates from 4 phylogeographic strains of the organism, we found that both host race/ethnicity and pathogen strain influence the innate immune response.

We found that macrophages from Filipinos produced less IL-1, IL-6, and more IL-8, compared to macrophages from Chinese and Whites participants. In response to the Toll-like receptor 2 agonist LTA, Filipino macrophages again had lower IL-1 and IL-6 responses and a higher IL-8 response, compared with Chinese and Whites. The TLR2/LTA-stimulated Filipino macrophages also produced lower amounts of IL-10, TNF $\alpha$  and GM-CSF, and the TLR4/LPS triggered the release of less IL-12p70 from Filipino macrophages, and less TNF $\alpha$  from White macrophages. These data would suggest that the induction of, IL-6, TNF- $\alpha$ , GM-CSF could be associated with TLR2 ligation. Unexpectedly, the induction of IL-8 appeared to be distinct from that of IL-6. In this regard, induction of both IL-6 and IL-8 via TLR-2 are both MyD88 dependent [25]. The differential response of IL-8 would imply either that other receptors might play a selective role in IL-8 induction. For example, the mannose receptor has been previously demonstrated to enable TLR-2 dependent IL-8 production. Similarly, Dectin1 and





**Fig 2. Cytokine response of macrophages to Toll-like receptor agonists by race/ethnicity.** Cytokines released by macrophages derived from healthy individuals of three ethnicities in response to TLR2 agonist lipoteichoic acid (LTA) and TLR4 agonist lipopolysaccharide (LPS). Comparisons are adjusted for age and gender. Brackets indicate FDR-adjusted  $p < 0.20$ .

<https://doi.org/10.1371/journal.pone.0195392.g002>

CD36 could modulate TLR responsiveness. Interestingly, *M. tuberculosis* can activate leukocytes via the mannose receptor [26], although this possibility has not been formally tested.

We also examined the effect of pathogen strain using lysates prepared from 4 *M. tuberculosis* strains: clinical strains Beijing HN878 (lineage 2), Manila T31 (lineage 1) and CDC1551 (lineage 4), and reference strain H37Rv (lineage 4). We found that CDC1551 elicited a markedly different macrophage response, for most of the cytokines, eliciting less IL-1, IL-6, IL-10, TNF $\alpha$ , and GM-CSF, and more IL-8, compared with other *M. tuberculosis* strains. These data would appear to parallel those seen for specific TLR-2 stimulation. Our data, then, would suggest that both differential responses to each strain, as well as those seen among the race/ethnic groups are driven by TLR-2 signalling, and would not support the original hypothesis that each strain would be “tuned” to its concordant, geographically-aligned host.

TB susceptibility and disease outcome vary greatly among individuals, and it is well established that at least some of this variability is attributable to host genetics [27–31]. Genetic loci that may influence clinical TB phenotypes have been identified [31–35]. Most of these genes encode immune response proteins [31, 36–38]. Here, responsiveness and/or production of IFN- $\gamma$  has been frequently observed as strongly associated with vulnerability to mycobacterial infection. With regard to TLRs it has been argued that TLR signaling specifically has “yet to provide convincing evidence of a major contribution of common variants of human TLRs, IL-1Rs, or their adaptors to host defense” [39]. Nonetheless, there a number of examples where specific TLRs or molecules related to TLR signaling can be associated with vulnerability to

**Table 2. Seven multivariable linear regression models predicting response of macrophages to *M. tuberculosis* lysates and race/ethnicity, adjusted for age and gender.** General estimating equation included to adjust for values clustered by participant. P values adjusted for multiple testing using the false discovery rate (FDR) method.

	IL-1		IL-6		IL-8		IL-10		IL-12p70		TNF $\alpha$		GM-CSF	
	Estimate (95%CI)	p value	Estimate (95%CI)	p value	Estimate (95%CI)	p value	Estimate (95%CI)	p value	Estimate (95%CI)	p value	Estimate (95%CI)	p value	Estimate (95%CI)	p value
<b>Race</b>														
White	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00
Chinese	0.06 (-0.41, 0.53)	.890	-0.05 (-0.67, 0.57)	.929	-0.02 (-0.21, 0.18)	.929	0.02 (-0.43, 0.47)	.949	-0.08 (-0.48, 0.32)	.868	0.19 (-0.05, 0.43)	.224	0.27 (-0.15, 0.70)	.332
Filipino	-0.76 (-1.2, -0.36)	.001	-0.70 (-1.2, -0.17)	.023	0.22 (0.04, 0.39)	.032	-0.15 (-0.57, 0.27)	.686	-0.20 (-0.66, 0.25)	.577	-0.11 (-0.37, 0.14)	.577	-0.12 (-0.52, 0.27)	.756
<b>Strain</b>														
H37RV	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00	Ref	1.00
CDC1551	-0.92 (-1.0, -0.79)	< .001	-1.2 (-1.3, -1.1)	< .001	0.51 (0.45, 0.57)	< .001	-1.0 (-1.1, -0.93)	< .001	-0.03 (-0.20, 0.14)	.868	-0.53 (-0.64, -0.43)	< .001	-1.0 (-1.1, -0.88)	< .001
HN878	-0.02 (-0.14, 0.10)	.868	-0.03 (-0.15, 0.08)	.787	-0.20 (-0.30, -0.10)	< .001	0.06 (-0.08, 0.19)	.577	0.18 (-0.05, 0.41)	.224	-0.16 (-0.29, -0.03)	.035	-0.15 (-0.26, -0.04)	.013
T31	0.20 (0.11, 0.30)	< .001	0.30 (0.21, 0.39)	< .001	-0.20 (-0.24, -0.15)	< .001	0.15 (0.10, 0.21)	< .001	0.17 (0.10, 0.24)	< .001	0.13 (0.07, 0.19)	< .001	0.20 (0.14, 0.27)	< .001
<b>Covariates</b>														
Age	-0.04 (-0.06, -0.02)	.001	-0.04 (-0.07, -0.01)	.025	0.02 (0.01, 0.03)	.002	0.00 (-0.02, 0.02)	.988	-0.04 (-0.06, -0.01)	.010	-0.01 (-0.03, 0.00)	.290	-0.03 (-0.05, -0.01)	.032
Male	0.07 (-0.36, 0.50)	.868	0.04 (-0.50, 0.58)	.929	-0.03 (-0.21, 0.15)	.868	-0.39 (-0.80, 0.02)	.121	0.32 (-0.04, 0.67)	.151	0.04 (-0.19, 0.27)	.868	0.06 (-0.33, 0.45)	.868

<https://doi.org/10.1371/journal.pone.0195392.t002>

infection with Mtb [15, 16], or to altered responsiveness to immunization with BCG [40]. Our data with regard to TLR2 responsiveness strongly supports genetic variation in TLR2 signaling.

The impact of ethnicity on TB susceptibility was revealed over a quarter century ago [41]. One of the first studies to dissect the relative influence of ethnicity and *M. tuberculosis* strain on TB disease phenotype showed that ethnicity is a powerful predictor of disease phenotype, independently of pathogen strain [42]. However, few studies have addressed the basis of these ethnic differences at the cellular and molecular levels. At the cellular level, one report has suggested that the ability of *M. tuberculosis* to grow in macrophages varies according to the ethnicity of the macrophage donor [43]. At the molecular level, a TLR2 polymorphism appears to be associated with TB susceptibility in Asians, but not in Caucasians [44], and inflammatory mediator levels are associated with ethnicity in pulmonary TB patients of African and Eurasian ancestry [45]. These ethnic differences are associated with ethnic variation in host vitamin D binding protein *DBP* phenotype, in accord with the demonstrated roles of the *DBP* protein in macrophage activation and neutrophil chemotaxis [46, 47]. Here, we show that macrophages derived from healthy Filipino donors had markedly different innate immune responses to *M. tuberculosis* lysate, to TLR2 stimulation with LTA, and to TLR4 stimulation with LPS, as compared with macrophages from non-Hispanic Whites and Chinese. It will be of interest to expand these studies to other ethnicities, including Africans, African-Americans and Hispanics.

At present, information regarding ethnic differences in TLR SNPs is limited. For example, one ethnic-specific difference is SNP TLR1 rs5743618 (changes T to G at bp 1805 and changes I to S at aa 602) [48]. This SNP regulates IL6 response to PAM3 stimulation, presumably via the ligation of the TLR1/2 heterodimer. The high responding variant is dominant in Asians (99% T) and Blacks (75%) while the low responding variant dominates in Whites and (75%). The entire TLR1/2/6 locus is an evolutionary hot spot under positive selection [48].

Many epidemiological and experimental studies have shown that *M. tuberculosis* strains produce different disease phenotypes and immune responses [20, 49–51]. This clinical phenotype diversity across *M. tuberculosis* strains is likely attributable to differing gene expression [51–53], metabolic profiles [54], cell wall lipids [55] and growth rates in macrophages [56]. We show here that clinical strain CDC1551 (lineage 4 modern) triggers the release of less IL-1, IL-6, IL-10, TNF $\alpha$ , and GM-CSF, and more IL-8, compared with clinical strains Beijing HN878 (lineage 2 modern), Manila T31 (lineage 1 ancient) and reference strain H37Rv (lineage 4 modern). Our results are in accord with those of Subbian et al, who reported that rabbits infected with CDC1551 produced less lung TNF $\alpha$  mRNA compared to rabbits infected with HN878, although, contrary to our data, they found that CDC1551 also triggered the production of less IL-8 mRNA [57]. As IL-8 is associated with neutrophilic inflammation, it was postulated that this was one reason that CDC1115 induced less cavitation. Manca et al. compared the innate immune responses elicited by strains CDC1551, HN878 and H37Rv, with results that are not congruent with our study. Mice infected with CDC1551 produced more IL-6 and IL-10 mRNA than HN878 and H37Rv, and more TNF $\alpha$  mRNA than HN878 [58, 59], and human monocytes infected with CDC1551 produced more IL-10 and TNF $\alpha$  mRNA than cells infected with HN878 [60]. These discordant results likely reflect different experimental systems, and it is notable that the earlier studies relied on small sample sizes.

The molecular bases for these innate immune response differences across host ethnicity and *M. tuberculosis* pathogen lineages are largely unknown. However, comparative genomics, and ongoing efforts to understand the unusual biology of these bacteria, including unbiased systems biology approaches [51, 61], are expected to yield insights. Furthermore, our work would support a detailed evaluation of TLR-2 dependent signaling across each of these species.

Our study has limitations, principally that our experimental system did not include a model in which macrophages were infected with live *M. tuberculosis*. We recognize that the use of cellular lysates represents a proxy of infection useful for comparisons rather than definitive determination of immunogenicity of strains. Also, whereas macrophages for all assays were enumerated at 50,000 cells/well, we did not enumerate circulating monocytes in volunteers nor evaluate for cell surface expression, which may have affected induced cytokine differences. Additionally, due to the multiplexed nature of assays and resource limitations, we were unable to conduct diluted assays, resulting in a censored upper limit of detection. Finally, ethnicity was determined based on self-report rather than genetic testing. Whereas, it has been shown that self-definitions of ethnicity are highly accurate reflection of true ethnic identity in Chinese and Whites, in particular, there is the potential for misclassification of ethnicity [62]. Our study also has a number of strengths. First, the immunologic responses to *M. tuberculosis* were evaluated using cells from healthy individuals and focused on innate immunity, thus reducing the influence of adaptive immunity, history of TB exposure, as well as environmental and socioeconomic factors. Second, our controlled experimental design allowed us to examine the interaction of host and pathogen genetics. Third, our study population of 137 healthy macrophage donors lends considerable robustness to our results.

In sum, our data show that that both host race/ethnicity and pathogen factors influence the innate immune response and such variation has implications for the development of new tools across TB therapeutics, immunodiagnostics and vaccines [3, 45, 63].

## Supporting information

**S1 Fig. Cytokine response of macrophages by *M. tuberculosis* strain.** Cytokines released by macrophages derived from healthy individuals of three ethnicities in response to *M. tuberculosis* lysates from four strains. Comparisons are adjusted for age and gender. Brackets indicate FDR-adjusted  $p < 0.20$ .

(DOCX)

**S1 Table. Cytokine response (geometric mean (GM) levels) of macrophages to lysates of four *M. tuberculosis* strains, by race/ethnicity, and adjusted for age and gender.** P values adjusted for multiple testing using the false discovery rate (FDR) method.

(DOCX)

**S2 Table. Cytokine response (geometric mean (GM) levels) of macrophages to TLR2 agonist LTA and TLR4 agonist LPS, by race/ethnicity, and adjusted for age and gender.** P values adjusted for multiple testing using the false discovery rate (FDR) method.

(DOCX)

**S3 Table. Cytokine response (geometric mean (GM) levels) of macrophages to *M. tuberculosis* lysates, by strain, and adjusted for age and gender.** General estimating equation is included to adjust for cytokine values clustered by participant. P values adjusted for multiple testing using the false discovery rate (FDR) method.

(DOCX)

## Acknowledgments

The authors would like to thank the following: Lynne Swarbrick, Megan Null for their support in the design, training and conduct of laboratory procedures and the study manual of operations. We thank Drs. A. Jayakumar, J.Y. Feng, D. Huang, L. Sheu, D. Osmond, for their input in the design and implementation of the experiments herein. We are grateful to the UCSF

Core Immunology Laboratory, Drs. Michael Inman, Elise Sambrano and Elizabeth Sinclair. We thank Dr. John Belisle for study design guidance and acquisition of isolates. We thank Dr. Sara Nakielny for scientific editing support. We thank Dr. Thomas Hawn (University of Washington) for his critical review and input of the manuscript.

## Author Contributions

**Conceptualization:** P. Nahid, M. Kato-Maeda, S. Gagneux, K. Dobos, P. C. Hopewell, D. M. Lewinsohn.

**Data curation:** P. Nahid, L. G. Jarlsberg, D. M. Lewinsohn.

**Formal analysis:** P. Nahid, L. G. Jarlsberg, M. R. Segal, D. H. Osmond, M. Gold, P. C. Hopewell, D. M. Lewinsohn.

**Funding acquisition:** P. Nahid, P. C. Hopewell, D. M. Lewinsohn.

**Investigation:** P. Nahid, S. Gagneux, K. Dobos, M. Gold, P. C. Hopewell, D. M. Lewinsohn.

**Methodology:** P. Nahid, L. G. Jarlsberg, M. Kato-Maeda, S. Gagneux, K. Dobos, M. Gold, P. C. Hopewell, D. M. Lewinsohn.

**Project administration:** P. Nahid, D. M. Lewinsohn.

**Resources:** P. Nahid, K. Dobos, P. C. Hopewell, D. M. Lewinsohn.

**Software:** P. Nahid, L. G. Jarlsberg, M. Gold, D. M. Lewinsohn.

**Supervision:** P. Nahid, M. Gold, P. C. Hopewell, D. M. Lewinsohn.

**Validation:** P. Nahid, L. G. Jarlsberg, M. R. Segal, D. H. Osmond, K. Dobos, M. Gold, D. M. Lewinsohn.

**Visualization:** P. Nahid, D. M. Lewinsohn.

**Writing – original draft:** P. Nahid, L. G. Jarlsberg, S. Gagneux, K. Dobos, P. C. Hopewell, D. M. Lewinsohn.

**Writing – review & editing:** P. Nahid, L. G. Jarlsberg, M. Kato-Maeda, S. Gagneux, K. Dobos, P. C. Hopewell, D. M. Lewinsohn.

## References

1. Filliol I, Driscoll JR, van Soolingen D, Kreiswirth BN, Kremer K, Valetudie G, et al. Snapshot of moving and expanding clones of *Mycobacterium tuberculosis* and their global distribution assessed by spoligo-typing in an international study. *J Clin Microbiol.* 2003; 41(5):1963–70. <https://doi.org/10.1128/JCM.41.5.1963-1970.2003> PMID: 12734235.
2. Ahmed N, Alam M, Rao KR, Kauser F, Kumar NA, Qazi NN, et al. Molecular genotyping of a large, multi-centric collection of tubercle bacilli indicates geographical partitioning of strain variation and has implications for global epidemiology of *Mycobacterium tuberculosis*. *J Clin Microbiol.* 2004; 42(7):3240–7. <https://doi.org/10.1128/JCM.42.7.3240-3247.2004> PMID: 15243088.
3. Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, et al. Influence of *M. tuberculosis* lineage variability within a clinical trial for pulmonary tuberculosis. *PLoS ONE.* 2010; 5(5):e10753. Epub 2010/05/28. <https://doi.org/10.1371/journal.pone.0010753> PMID: 20505778; PubMed Central PMCID: PMC2873999.
4. Brites D, Gagneux S. Co-evolution of *Mycobacterium tuberculosis* and *Homo sapiens*. *Immunol Rev.* 2015; 264(1):6–24. Epub 2015/02/24. <https://doi.org/10.1111/imir.12264> PMID: 25703549; PubMed Central PMCID: PMC4339235.
5. Wan X, Koster K, Qian L, Desmond E, Brostrom R, Hou S, et al. Genomic analyses of the ancestral Manila family of *Mycobacterium tuberculosis*. *PLoS One.* 2017; 12(4):e0175330. Epub 2017/04/11. <https://doi.org/10.1371/journal.pone.0175330> PMID: 28394899; PubMed Central PMCID: PMC5386241.

6. Filliol I, Driscoll JR, Van Soolingen D, Kreiswirth BN, Kremer K, Valetudie G, et al. Global distribution of *Mycobacterium tuberculosis* spoligotypes. *Emerg Infect Dis*. 2002; 8(11):1347–9. <https://doi.org/10.3201/eid0811.020125> PMID: 12453368.
7. Schorey JS, Schlesinger LS. Innate Immune Responses to Tuberculosis. *Microbiol Spectr*. 2016; 4(6). Epub 2017/01/15. <https://doi.org/10.1128/microbiolspec.TB2-0010-2016> PMID: 28087945.
8. Law K, Weiden M, Harkin T, Tchou-Wong K, Chi C, Rom WN. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. *Am J Respir Crit Care Med*. 1996; 153(2):799–804. <https://doi.org/10.1164/ajrccm.153.2.8564135> PMID: 8564135.
9. Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. *Immunology*. 1997; 90(4):607–17. PMID: 9176116.
10. Giacomini E, Iona E, Ferroni L, Miettinen M, Fattorini L, Orefici G, et al. Infection of human macrophages and dendritic cells with *Mycobacterium tuberculosis* induces a differential cytokine gene expression that modulates T cell response. *J Immunol*. 2001; 166(12):7033–41. PMID: 11390447.
11. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ, Goyert S, et al. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with *Mycobacterium tuberculosis*. *J Immunol*. 2002; 169(7):3480–4. PMID: 12244136.
12. Lazarus R, Vercelli D, Palmer LJ, Klimecki WJ, Silverman EK, Richter B, et al. Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. *Immunol Rev*. 2002; 190:9–25. PMID: 12493003.
13. Ferrand PE, Fujimoto T, Chennathukuzhi V, Parry S, Macones GA, Sammel M, et al. The CARD15 2936insC mutation and TLR4 896 A>G polymorphism in African Americans and risk of preterm premature rupture of membranes (PPROM). *Mol Hum Reprod*. 2002; 8(11):1031–4. PMID: 12397216.
14. Smirnova I, Mann N, Dols A, Derkx HH, Hibberd ML, Levin M, et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. *Proc Natl Acad Sci U S A*. 2003; 100(10):6075–80. <https://doi.org/10.1073/pnas.1031605100> PMID: 12730365.
15. Hawn TR, Misch EA, Dunstan SJ, Thwaites GE, Lan NT, Quy HT, et al. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. *Eur J Immunol*. 2007; 37(8):2280–9. Epub 2007/06/28. <https://doi.org/10.1002/eji.200737034> PMID: 17595679.
16. Randhawa AK, Shey MS, Keyser A, Peixoto B, Wells RD, de Kock M, et al. Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants. *PLoS Pathog*. 2011; 7(8):e1002174. Epub 2011/08/20. <https://doi.org/10.1371/journal.ppat.1002174> PMID: 21852947; PubMed Central PMCID: PMC3154845.
17. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, et al. Variable host-pathogen compatibility in *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A*. 2006; 103(8):2869–73. <https://doi.org/10.1073/pnas.0511240103> PMID: 16477032.
18. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, et al. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. *Nature*. 2004; 431(7004):84–7. <https://doi.org/10.1038/nature02837> PMID: 15343336.
19. Valway SE, Sanchez MP, Shinnick TF, Orme I, Agerton T, Hoy D, et al. An outbreak involving extensive transmission of a virulent strain of *Mycobacterium tuberculosis*. *N Engl J Med*. 1998; 338(10):633–9. <https://doi.org/10.1056/NEJM199803053381001> PMID: 9486991.
20. Lopez B, Aguilar D, Orozco H, Burger M, Espitia C, Ritacco V, et al. A marked difference in pathogenesis and immune response induced by different *Mycobacterium tuberculosis* genotypes. *Clin Exp Immunol*. 2003; 133(1):30–7. <https://doi.org/10.1046/j.1365-2249.2003.02171.x> PMID: 12823275.
21. Cattamanchi A, Hopewell PC, Gonzalez LC, Osmond DH, Masae Kawamura L, Daley CL, et al. A 13-year molecular epidemiological analysis of tuberculosis in San Francisco. *Int J Tuberc Lung Dis*. 2006; 10(3):297–304. PMID: 16562710.
22. Lucas MC, Wolfe LM, Hazenfield RM, Kurihara J, Kruh-Garcia NA, Belisle J, et al. Fractionation and analysis of mycobacterial proteins. *Methods Mol Biol*. 2015; 1285:47–75. Epub 2015/03/18. [https://doi.org/10.1007/978-1-4939-2450-9\\_4](https://doi.org/10.1007/978-1-4939-2450-9_4) PMID: 25779310.
23. Diggle P. Analysis of longitudinal data. Second Paperback Edition. ed. Oxford: Oxford University Press; 2013. xv, 379 pages p.
24. Efron B. Size, power and false discovery rates. *Ann Stat*. 2007; 35(4):1351–77. <https://doi.org/10.1214/009053606000001460> PubMed PMID: WOS:000249568000001.
25. Akira S, Takeda K. Toll-like receptor signalling. *Nat Rev Immunol*. 2004; 4(7):499–511. Epub 2004/07/02. <https://doi.org/10.1038/nri1391> PMID: 15229469.

26. Rajaram MV, Brooks MN, Morris JD, Torrelles JB, Azad AK, Schlesinger LS. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. *J Immunol*. 2010; 185(2):929–42. Epub 2010/06/18. <https://doi.org/10.4049/jimmunol.1000866> PMID: 20554962; PubMed Central PMCID: PMC3014549.
27. Kallmann FJ, Reisner D. Twin studies on the significance of genetic factors in tuberculosis. *Am Rev Tuberc*. 1942; 47:549–74.
28. Kramnik I, Dietrich WF, Demant P, Bloom BR. Genetic control of resistance to experimental infection with virulent *Mycobacterium tuberculosis*. *Proc Natl Acad Sci U S A*. 2000; 97(15):8560–5. Epub 2000/07/13. <https://doi.org/10.1073/pnas.150227197> PMID: 10890913; PubMed Central PMCID: PMC26987.
29. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. *Science*. 2012; 337(6102):1684–8. Epub 2012/08/04. <https://doi.org/10.1126/science.1224026> PMID: 22859821; PubMed Central PMCID: PMC3507439.
30. Bustamante J, Boisson-Dupuis S, Abel L, Casanova JL. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. *Semin Immunol*. 2014; 26(6):454–70. Epub 2014/12/03. <https://doi.org/10.1016/j.smim.2014.09.008> PMID: 25453225; PubMed Central PMCID: PMC357480.
31. Abel L, El-Baghdadi J, Bousfiha AA, Casanova JL, Schurr E. Human genetics of tuberculosis: a long and winding road. *Philos Trans R Soc Lond B Biol Sci*. 2014; 369(1645):20130428. Epub 2014/05/14. <https://doi.org/10.1098/rstb.2013.0428> PMID: 24821915; PubMed Central PMCID: PMC34024222.
32. Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. *PLoS One*. 2007; 2(12):e1318. Epub 2007/12/20. <https://doi.org/10.1371/journal.pone.0001318> PMID: 18091991; PubMed Central PMCID: PMC2117342.
33. Selvaraj P, Harishankar M, Singh B, Jawahar MS, Banurekha VV. Toll-like receptor and TIRAP gene polymorphisms in pulmonary tuberculosis patients of South India. *Tuberculosis (Edinb)*. 2010; 90(5):306–10. Epub 2010/08/28. <https://doi.org/10.1016/j.tube.2010.08.001> PMID: 20797905.
34. Boisson-Dupuis S, El Baghdadi J, Parvaneh N, Bousfiha A, Bustamante J, Feinberg J, et al. IL-12Rbeta1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. *PLoS One*. 2011; 6(4):e18524. Epub 2011/05/03. <https://doi.org/10.1371/journal.pone.0018524> PMID: 21533230; PubMed Central PMCID: PMC3076373.
35. Zhang Y, Jiang T, Yang X, Xue Y, Wang C, Liu J, et al. Toll-like receptor -1, -2, and -6 polymorphisms and pulmonary tuberculosis susceptibility: a systematic review and meta-analysis. *PLoS One*. 2013; 8(5):e63357. Epub 2013/05/22. <https://doi.org/10.1371/journal.pone.0063357> PMID: 23691034; PubMed Central PMCID: PMC3653945.
36. Azad AK, Sadee W, Schlesinger LS. Innate immune gene polymorphisms in tuberculosis. *Infect Immun*. 2012; 80(10):3343–59. Epub 2012/07/25. <https://doi.org/10.1128/IAI.00443-12> PMID: 22825450; PubMed Central PMCID: PMC3457569.
37. Meyer CG, Thye T. Host genetic studies in adult pulmonary tuberculosis. *Semin Immunol*. 2014; 26(6):445–53. Epub 2014/10/14. <https://doi.org/10.1016/j.smim.2014.09.005> PMID: 25307123.
38. Boisson-Dupuis S, Bustamante J, El-Baghdadi J, Camcioglu Y, Parvaneh N, El Azbaoui S, et al. Inherited and acquired immunodeficiencies underlying tuberculosis in childhood. *Immunol Rev*. 2015; 264(1):103–20. Epub 2015/02/24. <https://doi.org/10.1111/imr.12272> PMID: 25703555; PubMed Central PMCID: PMC34405179.
39. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. *Annu Rev Immunol*. 2011; 29:447–91. Epub 2011/01/12. <https://doi.org/10.1146/annurev-immunol-030409-101335> PMID: 21219179.
40. Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, et al. A Functional Toll-Interacting Protein Variant Is Associated with *Bacillus Calmette-Guerin*-Specific Immune Responses and Tuberculosis. *Am J Respir Crit Care Med*. 2017; 196(4):502–11. Epub 2017/05/04. <https://doi.org/10.1164/rccm.201611-2346OC> PMID: 28463648; PubMed Central PMCID: PMC5564674.
41. Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in susceptibility to infection by *Mycobacterium tuberculosis*. *N Engl J Med*. 1990; 322(7):422–7. <https://doi.org/10.1056/NEJM199002153220702> PMID: 2300105.
42. Pareek M, Evans J, Innes J, Smith G, Hingley-Wilson S, Loughheed KE, et al. Ethnicity and mycobacterial lineage as determinants of tuberculosis disease phenotype. *Thorax*. 2013; 68(3):221–9. Epub 2012/09/29. <https://doi.org/10.1136/thoraxjnl-2012-201824> PMID: 23019255.

43. Crowle AJ, Elkins N. Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli. *Infect Immun*. 1990; 58(3):632–8. PMID: [2106489](#).
44. Wang JJ, Xia X, Tang SD, Wang J, Deng XZ, Zhang Y, et al. Meta-analysis on the associations of TLR2 gene polymorphisms with pulmonary tuberculosis susceptibility among Asian populations. *PLoS One*. 2013; 8(10):e75090. Epub 2013/10/15. <https://doi.org/10.1371/journal.pone.0075090> PMID: [24124467](#); PubMed Central PMCID: [PMC3790778](#).
45. Coussens AK, Wilkinson RJ, Nikolayevskyy V, Elkington PT, Hanifa Y, Islam K, et al. Ethnic variation in inflammatory profile in tuberculosis. *PLoS Pathog*. 2013; 9(7):e1003468. Epub 2013/07/16. <https://doi.org/10.1371/journal.ppat.1003468> PMID: [23853590](#); PubMed Central PMCID: [PMC3701709](#).
46. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. *Clin Chim Acta*. 2006; 372(1–2):33–42. Epub 2006/05/16. <https://doi.org/10.1016/j.cca.2006.03.011> PMID: [16697362](#).
47. Chun RF, Lauridsen AL, Suon L, Zella LA, Pike JW, Modlin RL, et al. Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1,25-dihydroxyvitamin D. *J Clin Endocrinol Metab*. 2010; 95(7):3368–76. Epub 2010/04/30. <https://doi.org/10.1210/jc.2010-0195> PMID: [20427486](#); PubMed Central PMCID: [PMC2928899](#).
48. Barreiro LB, Ben-Ali M, Quach H, Laval G, Patin E, Pickrell JK, et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. *PLoS genetics*. 2009; 5(7):e1000562. Epub 2009/07/18. <https://doi.org/10.1371/journal.pgen.1000562> PMID: [19609346](#); PubMed Central PMCID: [PMC2702086](#).
49. Portevin D, Gagneux S, Comas I, Young D. Human macrophage responses to clinical isolates from the *Mycobacterium tuberculosis* complex discriminate between ancient and modern lineages. *PLoS Pathog*. 2011; 7(3):e1001307. Epub 2011/03/17. <https://doi.org/10.1371/journal.ppat.1001307> PMID: [21408618](#); PubMed Central PMCID: [PMC3048359](#).
50. Coscolla M, Gagneux S. Consequences of genomic diversity in *Mycobacterium tuberculosis*. *Semin Immunol*. 2014; 26(6):431–44. Epub 2014/12/03. <https://doi.org/10.1016/j.smim.2014.09.012> PMID: [25453224](#); PubMed Central PMCID: [PMC4314449](#).
51. Mvubu NE, Pillay B, Gamielidien J, Bishai W, Pillay M. *Mycobacterium tuberculosis* strains exhibit differential and strain-specific molecular signatures in pulmonary epithelial cells. *Dev Comp Immunol*. 2016; 65:321–9. Epub 2016/08/09. <https://doi.org/10.1016/j.dci.2016.07.022> PMID: [27497873](#).
52. Homolka S, Niemann S, Russell DG, Rohde KH. Functional genetic diversity among *Mycobacterium tuberculosis* complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. *PLoS Pathog*. 2010; 6(7):e1000988. Epub 2010/07/16. <https://doi.org/10.1371/journal.ppat.1000988> PMID: [20628579](#); PubMed Central PMCID: [PMC2900310](#).
53. Rose G, Cortes T, Comas I, Coscolla M, Gagneux S, Young DB. Mapping of genotype-phenotype diversity among clinical isolates of *mycobacterium tuberculosis* by sequence-based transcriptional profiling. *Genome Biol Evol*. 2013; 5(10):1849–62. Epub 2013/10/12. <https://doi.org/10.1093/gbe/evt138> PMID: [24115728](#); PubMed Central PMCID: [PMC3814196](#).
54. Khatri B, Fielder M, Jones G, Newell W, Abu-Oun M, Wheeler PR. High throughput phenotypic analysis of *Mycobacterium tuberculosis* and *Mycobacterium bovis* strains' metabolism using biolog phenotype microarrays. *PLoS One*. 2013; 8(1):e52673. Epub 2013/01/18. <https://doi.org/10.1371/journal.pone.0052673> PMID: [23326347](#); PubMed Central PMCID: [PMC3542357](#).
55. Portevin D, Sukumar S, Coscolla M, Shui G, Li B, Guan XL, et al. Lipidomics and genomics of *Mycobacterium tuberculosis* reveal lineage-specific trends in mycolic acid biosynthesis. *Microbiologyopen*. 2014; 3(6):823–35. Epub 2014/09/23. <https://doi.org/10.1002/mbo3.193> PMID: [25238051](#); PubMed Central PMCID: [PMC4263507](#).
56. Sarkar R, Lenders L, Wilkinson KA, Wilkinson RJ, Nicol MP. Modern lineages of *Mycobacterium tuberculosis* exhibit lineage-specific patterns of growth and cytokine induction in human monocyte-derived macrophages. *PLoS One*. 2012; 7(8):e43170. Epub 2012/08/24. <https://doi.org/10.1371/journal.pone.0043170> PMID: [22916219](#); PubMed Central PMCID: [PMC3420893](#).
57. Subbian S, Bandyopadhyay N, Tsenova L, O'Brien P, Khetani V, Kushner NL, et al. Early innate immunity determines outcome of *Mycobacterium tuberculosis* pulmonary infection in rabbits. *Cell Commun Signal*. 2013; 11:60. Epub 2013/08/21. <https://doi.org/10.1186/1478-811X-11-60> PMID: [23958185](#); PubMed Central PMCID: [PMC3765177](#).
58. Manca C, Tsenova L, Barry CE 3rd, Bergtold A, Freeman S, Haslett PA, et al. *Mycobacterium tuberculosis* CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. *J Immunol*. 1999; 162(11):6740–6. PMID: [10352293](#).
59. Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, Murray PJ, et al. Hypervirulent *M. tuberculosis* W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat

pathway. *J Interferon Cytokine Res.* 2005; 25(11):694–701. Epub 2005/12/02. <https://doi.org/10.1089/jir.2005.25.694> PMID: 16318583.

60. Manca C, Reed MB, Freeman S, Mathema B, Kreiswirth B, Barry CE 3rd, et al. Differential monocyte activation underlies strain-specific *Mycobacterium tuberculosis* pathogenesis. *Infect Immun.* 2004; 72(9):5511–4. <https://doi.org/10.1128/IAI.72.9.5511-5514.2004> PMID: 15322056.
61. Young D, Stark J, Kirschner D. Systems biology of persistent infection: tuberculosis as a case study. *Nat Rev Microbiol.* 2008; 6(7):520–8. Epub 2008/06/10. <https://doi.org/10.1038/nrmicro1919> PMID: 18536727.
62. Musser JM, Kroll JS, Granoff DM, Moxon ER, Brodeur BR, Campos J, et al. Global genetic structure and molecular epidemiology of encapsulated *Haemophilus influenzae*. *Rev Infect Dis.* 1990; 12(1):75–111. PMID: 1967849.
63. Divangahi M, Behr MA. Cracking the Vaccine Code in Tuberculosis. *Am J Respir Crit Care Med.* 2017. Epub 2017/10/19. <https://doi.org/10.1164/rccm.201707-1489PP> PMID: 29045159.